A Large Simple Safety Study of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease.

Trial Profile

A Large Simple Safety Study of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs Arformoterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms LSSS
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 20 Dec 2016 Results assessing changes in health status after adding arformoterol tartrate or placebo to patients treatment regimens, published in the Clinical Therapeutics journal.
    • 16 May 2016 Post-hoc analyses results published in the Media Release
    • 04 May 2016 Post-hoc analyses presented at the 2016 American Thoracic Society (ATS) International Conference, according to a Sunovion Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top